Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Neoplasms × adavosertib × Clear all

Phase

Status

Terminated 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Uterine Cervical Neoplasms 2 Advanced Solid Tumours 2 Vaginal Neoplasms 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Neoplasms 1 Myelodysplastic Syndromes 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Carcinoma, Endometrioid 1 Blast Crisis 1 Advanced Solid Tumors 1

Interventions

Gemcitabine 30 pembrolizumab 23 Cyclophosphamide 21 Paclitaxel 19 Irinotecan 18 Carboplatin 18 Docetaxel 17 Capecitabine 17 Fluorouracil 16 fludarabine 13 Leucovorin 13 Bevacizumab 13 Dexamethasone 12 Oxaliplatin 11 Everolimus 11 Erlotinib Hydrochloride 11 Blood Specimen Collection 11 Rituximab 10 Pemetrexed 10 venetoclax 9 Cisplatin 9 Cetuximab 9 Trastuzumab 8 Temozolomide 8 Nivolumab 7 aldesleukin 6 Sunitinib 6 Ipilimumab 6 Interleukin-2 6 Epoetin Alfa 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02576444 2022-12-28

OLAPCO

Yale University

Phase 2 Terminated

67 enrolled 10 charts

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡